Oct. 17 (Bloomberg) -- Vertex Pharmaceuticals Inc., seller of the hepatitis C drug Incivek, fell 3 percent after sales of the medicine were little changed.
Vertex, based in Cambridge, Massachusetts, dropped to $41.98 at 9:39 a.m. New York time. IMS Health Inc., a prescription-data company, said sales of Incivek in the first week of October were “relatively flat over September,” Jason Kantor, an analyst at RBC Capital Markets wrote in a note.
To contact the reporter on this story: Anna Edney in Washington at firstname.lastname@example.org
To contact the editor responsible for this story: Bruce Rule at email@example.com